Current and future biomarkers in allergic asthma.

Current and future biomarkers in allergic asthma.

Allergy. 2015 Dec 25;

Authors: Zissler UM, Bieren JE, Jakwerth CA, Chaker AM, Schmidt-Weber CB

Abstract
Diagnosis early in life, sensitization, asthma endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for allergic rhinitis and allergic asthma. The number of genes related to allergic rhinitis and allergic asthma increases steadily, however prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in respiratory inflammation to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore surface markers were grouped into cell-type specific categories. The current literature provides multiple biomarkers for potential asthma endotypes that are related to T cell phenotypes such as Th1, Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and neutrophilic asthma endotypes are also classified by epithelium-derived CCL-26 and osteopontin, respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of allergic rhinitis or allergic asthma classifiers with high prognostic value. This article is protected by copyright. All rights reserved.

PMID: 26706728 [PubMed - as supplied by publisher]

from #PubMed 1 via ola Kala on Inoreader http://ift.tt/1ORnE80
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IwOndF
via IFTTT